What top creators are saying about Keytruda(MRK)
Merck's cancer immunotherapy drug, pembrolizumab.
1 AI-extracted insight from 1 source — podcasts, YouTube channels, and X/Twitter accounts.
Creator sentiment — last 30 days
Based on 1 scored insight about Keytruda.
Top creators covering Keytruda (MRK)
The 1 sources with the most insights about Keytruda on Kazuha.
Latest insights about Keytruda (MRK)
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Yesterday
Keytruda was cited as a sales benchmark at about $33 billion for the year discussed. The speaker noted biosimilar competition and potential difficulty extending its product life.
Yesterday
Keytruda was cited as a sales benchmark at about $33 billion for the year discussed. The speaker noted biosimilar competition and potential difficulty extending its product life.
Discussed alongside Keytruda (MRK)
Other assets that creators frequently mention in the same content as Keytruda.
Frequently asked
Which podcasters and creators cover Keytruda (MRK) the most?
The most active sources covering Keytruda (MRK) on Kazuha are @shkreliplanet. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
How many insights about Keytruda (MRK) are on Kazuha?
Kazuha has indexed 1 AI-extracted insight about Keytruda (MRK) from 1 different source. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
What other assets do creators discuss alongside Keytruda (MRK)?
Creators covering Keytruda (MRK) most frequently also discuss IREN, Celast Life Sciences, MRK, SLNS, CRWV. See the "Discussed alongside" section above for full asset pages.